7 years ago

KaNDy Therapeutics Raises £25M in Series C Financing for Menopause Treatment

  • KaNDy Therapeutics, a UK-based clinical-stage Women's Health company, has closed a £25m Series C financing round

  • The company plans to use the funds to advance its non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause.

      • ProblemHealthcare

      "treating multiple symptoms of menopause"

      Solution

      "once-a-day oral, small molecule dual antagonist of both the neurokinin-1 and 3 receptors"

      Covered on